What is the 13F Pro Quality Score for RXST?

13F Pro ranks RxSight, Inc. (RXST) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View RXST's current score at https://13fpro.ai/research/RXST (free sign-up required for the full ranking).

Where does 13F Pro source RXST data?

All RxSight, Inc. fundamentals and ownership data come directly from SEC EDGAR. RxSight, Inc. files with the SEC under CIK 1111485. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is RXST in?

RxSight, Inc. (RXST) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is RXST research updated on 13F Pro?

RXST's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

RxSight, Inc.(RXST)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1111485 RXST stock profile & AI dashboard →

13F Pro Quality Score

32.0/100

Rank #2,289 of 2,879 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

81.8/100

Profitability

11.9/100

Balance Sheet

14.0/100

Earnings Quality

30.0/100

Free Cash Flow

13.5/100

Institutional Flow

84.5/100

Revenue Scale

20.2/100

Dilution Risk

8.0/100

RXST Stock Analysis & AI Quality Score

AI stock analysis and institutional research for RxSight, Inc. (RXST), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores RXST at 32.0/100 on a 32-signal composite quality model, placing it at rank #2,289 of 2,879 stocks — the bottom half of the AI-ranked universe. RXST scores in the top quartile across institutional flow (84.5), revenue growth (81.8). Areas of concern include profitability (11.9) and free cash flow (13.5), which score below median versus the broader universe. Shareholder dilution risk is elevated at 8.0/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), RxSight, Inc. reports quarterly revenue of $30.9M, net income of $-15.9M, free cash flow of $-11.7M. Top institutional holders of RXST by reported 13-F value include BlackRock,, MILLENNIUM MANAGEMENT, Artisan Partners Limited Partnership, based on the most recent SEC filings. RXST trades on the Nasdaq exchange and files with the SEC under CIK 1111485. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate RXST daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for RxSight, Inc. directly from SEC EDGAR. RxSight, Inc.'s 13F Pro composite quality score has ranged between 8 and 62 since 2022, currently 32.0 — a stable long-term trajectory across 52 quarterly and live scoring snapshots.

✦

Fun facts about RxSight, Inc.

Quirks, history, and lore behind RXST — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. medical device company · small-cap · listed on Nasdaq · headquartered in Southern California.
2
The Numbers
Annual revenue in the tens of millions of dollars — this is an early-commercial-stage company burning cash while it tries to reshape a massive surgical market.
3
The History
Founded in the early 2000s, it spent years in development and clinical trials before earning FDA approval for a novel implantable lens system — then went public on Nasdaq around 2022.
4
The Secret
Unlike traditional fixed implants, its device is adjustable after surgery — a doctor can fine-tune the patient's vision using a UV light delivery system weeks after the operation.
5
The Lore
Its technology targets the roughly 4 million cataract surgeries performed in the U.S. each year, promising patients a level of post-op precision that standard intraocular lenses simply can't offer.
6
The Giveaway
Its name practically tells you the whole story: it's in the business of giving patients adjustable vision after cataract surgery, with a Light Adjustable Lens that is tuned — quite literally — by light.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q1 2026

$30.9M

Net Income

Q1 2026

$-15.9M

Free Cash Flow

Q1 2026

$-11.7M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

-3.9% YoY

$134.5MFY 2025

FY21 $22.6MFY22 $49.0MFY24 $139.9MFY25 $134.5M

Net Income

-41.8% YoY

$-38.9MFY 2025

FY21 $-48.7MFY22 $-66.80FY24 $-27.5MFY25 $-38.9M

Operating Income

-30.7% YoY

$-48.2MFY 2025

FY21 $-52.8MFY22 $-63.3MFY24 $-36.9MFY25 $-48.2M

EPS (Diluted)

-33.8% YoY

$-0.95FY 2025

FY21 $-3.57FY22 $-2.41FY24 $-0.71FY25 $-0.95

Total Assets

-2.1% YoY

$311.8MFY 2025

FY21 $192.7MFY22 $150.2MFY24 $318.6MFY25 $311.8M

Total Debt

—FY 2025

FY21 $39.8MFY22 $40.2MFY24 —FY25 —

Op. Cash Flow

+8.5% YoY

$-15.5MFY 2025

FY21 $-44.7MFY22 $-58.9MFY24 $-16.9MFY25 $-15.5M

Metric	FY 2025	FY 2024	FY 2022	FY 2021
Revenue	$134.5M -3.9%	$139.9M +185.5%	$49.0M +116.9%	$22.6M
Net Income	$-38.9M -41.8%	$-27.5M -41100199.4%	$-66.80 +100.0%	$-48.7M
Operating Income	$-48.2M -30.7%	$-36.9M +41.8%	$-63.3M -19.9%	$-52.8M
EPS (Diluted)	$-0.95 -33.8%	$-0.71 +70.5%	$-2.41 +32.5%	$-3.57
Total Assets	$311.8M -2.1%	$318.6M +112.1%	$150.2M -22.1%	$192.7M
Total Debt	—	—	$40.2M +1.0%	$39.8M
Operating Cash Flow	$-15.5M +8.5%	$-16.9M +71.2%	$-58.9M -31.6%	$-44.7M

AI Insight: RXST Financial Trends

RxSight revenue has fallen from $40M in Q4 2024 to $31M in Q1 2026 while net losses deepened to $16M, the worst in the dataset.

• Revenue declined from a peak of $40M in Q4 2024 to $31M in Q1 2026, a 22.5% drop over five quarters.

• Net loss widened sharply to $16M in Q1 2026 from $6M in Q2 2024, the largest quarterly loss in the period.

• Operating cash outflow hit $11M in Q1 2026, matching the worst quarter (Q1 2025) and reversing brief improvement in Q3–Q4 2025.

• Equity eroded from $281M in Q4 2024 to $267M in Q1 2026, reflecting cumulative net losses with no debt reported.

⚠ Operating losses deepened to $18M in Q1 2026 from $11M in Q4 2025 — the steepest single-quarter deterioration in the dataset.

⚠ Equity has declined four consecutive quarters; continued losses risk meaningfully depleting the $267M remaining equity cushion.

⚠ Revenue seasonality is unclear — Q1 weakness recurs, but Q1 2026 at $31M is the lowest quarterly print observed.

AI Insight: RXST Ratio Trends

RxSight's losses are accelerating sharply: Q1 2026 operating margin collapsed to -57.7%, the worst in the dataset, signaling mounting cost pressure.

• Operating margin deteriorated from -21.5% in Q4 2024 to -57.7% in Q1 2026, a roughly 36pp swing deeper into losses.

• Net profit margin worsened from -14.8% in Q4 2024 to -51.4% in Q1 2026, accelerating cash consumption.

• ROIC fell from -12.3% in Q4 2024 to -26.7% in Q1 2026, reflecting increasingly poor returns on invested capital.

• ROA dropped from -7.5% in Q4 2024 to -20.9% in Q1 2026, indicating assets are generating deeper losses each quarter.

⚠ Q1 2026 OpMargin of -57.7% is the single worst quarter recorded — monitor whether this reflects a structural shift or seasonal spike.

⚠ D/E data is absent across all periods; inability to assess leverage adds uncertainty to the balance sheet outlook.

⚠ Q4 2024 showed relative improvement across all metrics — watch Q4 2026 to see if seasonal recovery repeats or fades.

Get alerted when RXST's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for RxSight, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of RXST

BlackRock, Inc.
$19.6M3,187,092 sh
MILLENNIUM MANAGEMENT LLC
$12.7M2,059,459 sh
Artisan Partners Limited Partnership
$12.7M2,058,684 sh
NOMURA HOLDINGS INC
$12.3M2,000,060 sh
No Street GP LP
$12.3M2,000,000 sh
D. E. Shaw & Co., Inc.
$12.1M1,959,732 sh
VANGUARD CAPITAL MANAGEMENT LLC
$10.4M1,692,935 sh
TWO SIGMA INVESTMENTS, LP
$8.0M1,300,260 sh
BANK OF AMERICA CORP /DE/
$7.5M1,210,039 sh
HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND
$7.0M1,131,400 sh

Fund	Value	Shares
BlackRock, Inc.	$19.6M	3,187,092
MILLENNIUM MANAGEMENT LLC	$12.7M	2,059,459
Artisan Partners Limited Partnership	$12.7M	2,058,684
NOMURA HOLDINGS INC	$12.3M	2,000,060
No Street GP LP	$12.3M	2,000,000
D. E. Shaw & Co., Inc.	$12.1M	1,959,732
VANGUARD CAPITAL MANAGEMENT LLC	$10.4M	1,692,935
TWO SIGMA INVESTMENTS, LP	$8.0M	1,300,260
BANK OF AMERICA CORP /DE/	$7.5M	1,210,039
HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND	$7.0M	1,131,400

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put RXST on your watchlist

Track score changes the day RxSight, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is RXST a good stock to buy?

13F Pro's AI-powered analysis of RxSight, Inc. (RXST) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for RXST are available on the RXST stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own RXST?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling RXST. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of RxSight, Inc.'s investment landscape.